Understanding the UK CBD Novel Foods Status under the FSA Article 4
Matters more than ever. Regulatory uncertainty now shapes product launches, labeling and market access.
Because rules can affect thousands of products, brands need clarity fast.
Since 2019 the Food Standards Agency signaled CBD should be regulated as novel foods.
However, delays and governance questions have left many businesses unsure.
As a result, legal challenges and Article 4 submissions have gained traction.
The Hearth Hound Article 4 claim argues whole-plant hemp foods may not be novel.
If accepted, the decision could reshape how regulators classify hemp extracts.
This debate affects full-spectrum and broad-spectrum extracts and cold-pressed oils.
In this article we unpack the Article 4 challenge.
We also cover recent Freedom of Information findings and the FSA response.
Finally, we outline what brands should do to manage risk and compliance.
Expect practical steps, timelines and risk mitigation advice for brands and retailers.
Therefore, read on to stay ahead of compliance shifts and regulatory risk.
UK CBD novel foods status under the FSA Article 4
Regulatory background
Understanding the UK CBD novel foods status under the FSA Article 4 matters for every producer and retailer. Since 2019 the Food Standards Agency has signalled that cannabidiol products should fall under the novel foods framework. As a result, businesses must follow the FSA novel foods authorisation route. The FSA explains its approach in detail here FSA Novel Foods Guidance.
In late 2025 an Article 4 submission led by Hemp Hound questioned whether some whole plant hemp foods are truly novel. For example the submission argues cold pressed hemp oil has a history of consumption. Coverage of that Article 4 filing appears here Hemp Hound Article 4 Submission Coverage.
What Article 4 seeks to do
Article 4 allows businesses to present evidence that a food has a history of consumption in the UK or EU before 1997. If successful regulators may decide the product is not novel. Therefore the Article 4 route can prevent the need for full novel food authorisation.
Compliance requirements
Businesses should treat Article 4 as a technical legal claim. However they must still prepare safety dossiers if regulators deem the product novel. In addition firms must register products on the FSA public register and track status updates. As of early 2026 the register listed 11,456 CBD products, many still awaiting evidence or assessment.
Implications for consumers and businesses
For consumers the debate affects product availability and safety oversight. For businesses it drives labeling choices, supply chain checks and liability planning. Consequently firms face both commercial and regulatory risk until clarity improves.
Key compliance steps
- Compile robust historical consumption evidence and citations
- Produce a quality safety assessment and method of manufacture details
- Register products on the FSA public register and monitor status
- Maintain batch testing, THC controls and clear labeling to reduce risk
- Seek legal advice before relying solely on Article 4 arguments
This clear framework will help brands navigate novel food uncertainty, protect consumers and reduce regulatory risk.
Industry impact: UK CBD novel foods status under the FSA Article 4
Regulatory uncertainty now shapes product lines and investment decisions. Because the Article 4 claim challenges the default novel foods approach, firms face short and long term consequences. As of early 2026 the Food Standards Agency public register listed 11,456 CBD products. Specifically about 10,200 were awaiting evidence, 900 were under safety assessment, 250 were in risk management, 106 were authorised or green lighted, and 409 had been removed or disqualified. For full context see the FSA update at here.
Because the Hearth Hound Article 4 filing questions whether whole plant hemp foods are novel, some companies expect faster market access if the claim succeeds. However others worry about inconsistent outcomes. As a result industry consolidation may continue, and innovation funding could slow. The Article 4 process itself has also raised governance questions, because FOI disclosures showed a meeting record gap. Read more on the filing and FOI concerns at this link and this link.
Consumer safety implications
Regulators and brands must prioritise safety while uncertainty persists. Therefore firms should keep robust batch testing, THC controls and clear labeling. Moreover the FSA still advises caution around CBD, and it publishes practical guidance at this resource. Consequently consumers may see fewer products on shelves in the short term, but higher scrutiny overall.
Key impacts at a glance
- Market access: delays raise compliance costs and slow product launches
- Innovation: investment risk increases, so product R&D may decline
- Trust and transparency: governance questions can erode consumer confidence
- Safety oversight: stricter testing and traceability become table stakes
In sum the UK CBD novel foods status under the FSA Article 4 affects supply, safety and market trust. Therefore brands must plan for multiple outcomes, and they should document safety and history of consumption evidence now.
Comparative regulatory snapshot: UK, EU, US
Below is a compact, accessible comparison of CBD regulatory approaches in the United Kingdom, European Union and United States. The table highlights permitted products, application routes, typical timelines and consumer safety controls to help brands map compliance risk and plan market entry. Keywords: CBD regulation, cannabidiol, novel foods, historical use, Article 4, EFSA, FDA, compliance, traceability.
| Jurisdiction | Permitted products | Application process | Typical timelines | Consumer safety measures |
|---|---|---|---|---|
| United Kingdom | Most CBD treated as novel unless historic use proven; full spectrum and cold pressed oils often questioned | Novel foods authorisation or Article 4 historical use claim with evidentiary dossier | Months to years; many products remain on the FSA public register | Batch testing, THC limits, manufacturing controls and clear labelling. See FSA guidance and register: FSA guidance and FSA public list |
| European Union | CBD and hemp extracts listed as novel; full spectrum extracts regulated tightly | EU novel food application to EFSA with a technical safety dossier | Often 18 months plus; extended when data gaps exist | Pre market safety assessment, residue testing and harmonised labelling. See EU novel food catalogue: EU novel food catalogue |
| United States | FDA has not approved CBD in foods or dietary supplements generally | No established FDA novel food route for CBD; firms face potential enforcement risk | Variable; guidance and enforcement evolve over time | FDA advises caution against marketing CBD foods and supplements; industry relies on testing and voluntary standards. See FDA guidance: FDA guidance |
Use this snapshot to prioritise evidence gathering, testing and regulatory mapping for each target market.
Conclusion
The UK CBD novel foods status under the FSA Article 4 remains a pivotal issue for the market. Because the Article 4 challenge could change how whole plant hemp foods are classified, firms must stay alert. Regulators still expect robust safety data, and many products remain on the FSA public register. Therefore brands should document history of consumption and safety testing now.
Understanding the framework benefits both consumers and businesses. For consumers it means clearer labeling, tighter THC controls and better product safety. For businesses it reduces legal risk, protects brand reputation and supports sustainable innovation. Moreover MyCBDAdvisor provides full spectrum, research driven guidance to help brands and shoppers navigate this landscape. Also note the brand identity tag EMP0 for alignment and tracking.
Looking ahead the market can become more stable and trustworthy. However outcomes will depend on evidence quality and regulatory decisions. Consequently prepare for multiple scenarios, communicate transparently and invest in testing and traceability. In doing so stakeholders protect consumers and unlock long term growth.
Frequently Asked Questions (FAQs)
What is the Article 4 challenge and why does it matter?
Article 4 lets businesses show a food had significant consumption before 1997. Because the Hearth Hound filing argues some whole plant hemp foods are historic, the claim could change classifications. Therefore it matters for market access and regulatory burden.
Does a successful Article 4 claim guarantee products stay on the market?
No. A successful claim may avoid novel food authorisation. However regulators still expect safety data and testing. As a result firms must keep controls and records.
How does this status affect consumers and safety?
Consumers may see fewer products short term. Nevertheless higher scrutiny improves labeling and THC control over time. Consequently safety oversight should strengthen.
Which products are most affected?
Full spectrum extracts, broad spectrum extracts and cold pressed hemp oil face close review. Moreover tinctures and concentrated extracts often need detailed dossiers.
What should brands do now?
Compile historical use evidence and safety studies. Then register products on the FSA list and maintain batch testing. Finally seek legal advice before relying solely on Article 4 claims.
